3. How safe is the treatment?
Xeomin® was proven effective in two randomized, double-blind, multicenter, placebo-controlled clinical trials of 547 healthy, adult patients. The average age of patients in the study was 46 years.
Patients received 20 Units of Xeomin® and were classified as responders if they had a 2-grade improvement on a 4-point scale as assessed by the physician and patient.
Using these criteria, treatment success was higher with Xeomin® than placebo on Day 30 in both studies (60% and 48% vs. 0% for placebo in both studies).
Based on these trials, Xeomin® received FDA approval for use in glabellar lines in 2011.
4. How is Xeomin® different from other brands?
Xeomin® is made through a unique precision manufacturing process that isolates the therapeutic component of the molecule and removes the accessory proteins that don’t play an active role in treatment.
Xeomin® is a highly purified neurotoxin. Studies have not been performed to determine whether the presence or absence of accessory proteins has a long-term effect on safety or efficacy.